Copyright ©The Author(s) 2017.
World J Clin Oncol. Apr 10, 2017; 8(2): 145-150
Published online Apr 10, 2017. doi: 10.5306/wjco.v8.i2.145
Table 1 Summary of the phase I/II trials of immunotherapies in sarcoma
Treatment modalityRef.AgentPhase/PatientsIndicationRRSurvival
Adoptive cell therapyRobbins et al[31], 2011Adoptively transferred autologous T cells transduced with a T-cell receptor directed against NY-ESO-1I/6Metastatic synovial cell sarcoma expressing NY-ESO-1RR: 4/6N/A
VaccinesMahvi et al[34], 2002GM-CSF treated tumor cellsI/16Melanoma and sarcomasRR: 1/16N/A
Dillman et al[35], 2004Autologous tumor cell line-derived vaccinesI, II/23Recurrent or metastatic sarcomaNo objective response assessed10 patients lived more than 1 year
Kawaguchi et al[36], 2005Vaccination By SYT-SSX junction peptideI/6Disseminated synovial sarcomaRR: 0/6N/A
Kawaguchi et al[38], 2012SYT-SSX breakpoint peptide vaccinesI, II/21Metastatic synovial sarcomaRR: 1/21 SD: 6/21N/A
Takahashi et al[39], 2013Personalized peptide vaccinationII/20Refractory bone and soft tissue sarcomaSD in all patientsMedian OS: 9.6 mo
Finkelstein et al[40], 2012Combination of external beam radiotherapy with intratumoral injection of dendritic cellsI, II/17Neoadjuvant treatment in high-risk soft tissue sarcomaRR: 9/17One-year PFS: 70.6%
Ghisoli et al[41], 2015FANG autologous immunotherapyI/12Advanced and metastatic Ewing's sarcomaRR: 1/12One-year OS: 75%
Checkpoint inhibitorsMakki et al[44], 2013IpilimumabII/6Advanced synovial sarcomaRR: 0/6 (closed prematurely)Median OS: 8.75 mo